

MEDAREX INC  
Form 8-K  
September 25, 2002  
Table of Contents

---

As filed with the Securities and Exchange Commission on September 25, 2002.

---

**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)  
September 25, 2002 (September 24, 2002)

---

**MEDAREX, INC.**

(Exact name of registrant as specified in its charter)

New Jersey  
(State of other jurisdiction of incorporation)

0-19312  
(Commission File Number)

22-2822175  
(IRS Employer Identification No.)

707 State Road, Princeton, N.J. 08540-1437  
(Address of Principal Executive Offices)

Registrant's telephone number, including area code: (609) 430-2880

Not Applicable  
(Former name or former address, if changed since last report)

---

**Table of Contents**

**MEDAREX, INC.  
TABLE OF CONTENTS  
FOR  
CURRENT REPORT ON FORM 8-K**

<u>Item 5. Other Events</u>	3
<u>Item 7. Financial Statements and Exhibits</u>	3
<u>Signature</u>	4

**Table of Contents**

**Item 5. Other Events.**

On September 24, 2002, our partner Genmab A/S issued a press release in which it publicly announced that its HuMax-CD4 product, a fully human antibody that targets the CD4 receptor on cells known as T-cells, was found not to be effective in combination with methotrexate in a Phase II study of 155 patients with active rheumatoid arthritis. A copy of the relevant portions of Genmab's press release is attached hereto as Exhibit 10.1.

We have a collaboration with Genmab relating to the use of our fully human antibody technology for the development of therapeutic fully human antibody products and we currently have an equity interest of approximately 30% in Genmab.

**Item 7. Financial Statements and Exhibits.**

(c) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:

**Exhibit  
Number**

---

10.1 Excerpt from Genmab A/S Press Release dated September 24, 2002.

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDAREX,INC.  
Registrant

Date: September 25, 2002

By: /s/ Christian S. Schade

---

Christian S. Schade  
Senior Vice President and Chief Financial Officer

4

**Table of Contents**

**EXHIBIT INDEX**

<b><u>Exhibit Number</u></b>	<b><u>Description</u></b>	<b><u>Page Number</u></b>
10.1	Excerpt from Genmab A/S Press Release dated September 24, 2002	